(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2012 (11.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/136549 A1

(51) International Patent Classification:
*A61K 31/517* (2006.01) *A61P 35/00* (2006.01)
*G01N 33/48* (2006.01)

(21) International Application Number:
PCT/EP2012/055595

(22) International Filing Date:
29 March 2012 (29.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11161142.2 5 April 2011 (05.04.2011) EP

(71) Applicant *(for all designated States except US)*: **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müller Strasse 178, 13353 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LIU, Ningshu** [DE/DE]; Limonenstr. 28, 12203 Berlin (DE). **SCHNEIDER, Claudia** [DE/DE]; Bastianstr. 10, 13357 Berlin (DE).

(74) Agent: **BAYER PHARMA AKTIENGESELLSCHAFT**; Law and Patents, Patents and Licensing, Müller Strasse 178, 13353 Berlin (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published**:

— *with international search report (Art. 21(3))*

WO 2012/136549 A1

(54) **Title**: USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES

(57) **Abstract**: The present invention relates to: - use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; - combinations of a) said compound and b) one or more further active agents; - a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; - a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; - use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and / or loss of PTEN for predicting the sensitivity and /or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and - a method of determining the level of a component of one or more of Bcl expression, HER family expression and/or activation, PIK3CA signaling and / or loss of PTEN.